<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39387989</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.</ArticleTitle><Pagination><StartPage>2255</StartPage><EndPage>2283</EndPage><MedlinePgn>2255-2283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01052-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The United States Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control (CDC) recommend COVID-19 vaccines for all immunocompromised individuals. Certain disease groups are at increased risk of comorbidity and death for which disease-specific recommendations should be considered. The objective of the Delphi panel of experts was to summarize expert consensus on COVID-19 vaccinations for patients with rheumatologic disease, renal disease, hematologic malignancy and solid organ transplant (SOT) in the US.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A two-stage Delphi panel method was employed, starting with qualitative interviews with key opinion leaders (KOLs) in the four disease areas (n = 4 KOLs, n = 16 total) followed by three rounds of iterative revision of disease-specific COVID-19 vaccine recommendations. Final consensus was rated after the third round. Statements addressed primary and booster dosing (e.g., number and frequency) and other considerations such as vaccine type or heterologous messenger ribonucleic acid (mRNA) vaccination. Following the Delphi Panel, an online survey was conducted to assess physician agreement within the disease areas (n = 50 each, n = 200 total) with the consensus statements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Moderate to strong consensus was achieved for all primary series vaccination statements across disease groups, except one in hematology. Similarly, moderate to strong consensus was achieved for all booster series statements in all disease areas. However, statements on antibody titer measurements for re-vaccination considerations and higher dosages for immunocompromised patients did not reach agreement. Overall, approximately 62%-96% of physicians strongly agreed with the primary and booster vaccine recommendations. However, low agreement (29%-69%) was found among physicians for time interval between disease-specific treatment and vaccination, recommendations for mRNA vaccines, heterologous mRNA vaccination, antibody titer measurement and higher vaccine dosage for immunocompromised groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Consensus was achieved for disease-specific COVID-19 vaccine recommendations concerning primary and booster series vaccines and was generally well accepted by practicing physicians.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kira Zhi Hua</ForeName><Initials>KZH</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenstein</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Westchester Medical Center, Transplant Surgery, 100 Woods Road, Valhalla, NY, 10595, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govindasamy</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>UPMC Hamot Medical Center, Erie, PA, 16550, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paranilam</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimball-Carroll</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4229-695X</Identifier><AffiliationInfo><Affiliation>ICON Clinical Research, Dublin 18, Ireland. Samantha.kimball@iconplc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>7700053394</GrantID><Agency>Moderna</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Hematologic malignancy</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Renal disease</Keyword><Keyword MajorTopicYN="N">Rheumatologic disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">Solid organ transplant</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Kira Zhi Hua Lai, Jaya Paranilam, Joseph Brown, Samantha Kimball-Carroll are employed by ICON Plc and have previously worked with Moderna Inc. Stuart Greenstein and Rajesh Govindasamy have nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39387989</ArticleId><ArticleId IdType="pmc">PMC11499552</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01052-8</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01052-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023;14:1204831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10523015</ArticleId><ArticleId IdType="pubmed">37771594</ArticleId></ArticleIdList></Reference><Reference><Citation>Panel C-TG. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway JP, Tideman S, French T, Wright B, Parsons G, Diaz G, et al. Odds of hospitalization for COVID-19 after 3 vs 2 doses of mRNA COVID-19 vaccine by time since booster dose. JAMA. 2022;328(15):1559–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9508676</ArticleId><ArticleId IdType="pubmed">36149677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao G, Wang Y, Qi X, Nasr B, Bao M, Gao M, et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando). 2021;35(3): 100628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137345</ArticleId><ArticleId IdType="pubmed">34087553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Shao SC, Chen YT, Hsu CK, Hsu HJ, Lee CC, et al. Incidence and clinical impacts of COVID-19 infection in patients with hemodialysis: systematic review and meta-analysis of 396,062 hemodialysis patients. Healthcare (Basel). 2021;9(1):47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824817</ArticleId><ArticleId IdType="pubmed">33466527</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011807</ArticleId><ArticleId IdType="pubmed">34807517</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, Möller B, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423431</ArticleId><ArticleId IdType="pubmed">34514436</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179144</ArticleId><ArticleId IdType="pubmed">35698725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Risk M, Schiopu E, Hayek SS, Xie T, Holevinski L, et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis. 2022;81(6):875–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9422955</ArticleId><ArticleId IdType="pubmed">35197265</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021;9: 100178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299287</ArticleId><ArticleId IdType="pubmed">34318288</ArticleId></ArticleIdList></Reference><Reference><Citation>(ACIP) ACoIP. ACIP evidence to recommendations for use of an additional COVID-19 vaccine dose in immunocompromised people. In: Control USCfD, editor. 2024.</Citation></Reference><Reference><Citation>Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 4. Arthritis Rheumatol. 2022;74(5):e21–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082483</ArticleId><ArticleId IdType="pubmed">35474640</ArticleId></ArticleIdList></Reference><Reference><Citation>Au WY, Cheung PPH. Effectiveness of heterologous and homologous Covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377: e069989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724446</ArticleId><ArticleId IdType="pubmed">35640925</ArticleId></ArticleIdList></Reference><Reference><Citation>Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, et al. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int. 2022;101(2):390–402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628628</ArticleId><ArticleId IdType="pubmed">34856313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira VH, Ierullo M, Mavandadnejad F, Kurtesi A, Hu Q, Hardy WR, et al. Omicron BA.4/5 Neutralization and T-cell responses in organ transplant recipients after booster messenger RNA vaccine: a multicenter cohort study. Clin Infect Dis. 2023;77(2):229–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">36975097</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjallé R, et al. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. Haematologica. 2022;107(8):1840–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9335098</ArticleId><ArticleId IdType="pubmed">34911284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti M, Rinaldi M, Bussini L, Bonazzetti C, Pascale R, Pasquini Z, et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(8):1057–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8916831</ArticleId><ArticleId IdType="pubmed">35289294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge C, Du K, Luo M, Shen K, Zhou Y, Guo K, et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022;11(1):46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380660</ArticleId><ArticleId IdType="pubmed">35974381</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191–204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8874732</ArticleId><ArticleId IdType="pubmed">35217850</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarhaus M, Duhanes M, Leševic N, Matei B, Ramsauer B, Da Silva RR, et al. Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients. Scand J Immunol. 2022;95(5): e13152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115353</ArticleId><ArticleId IdType="pubmed">35244289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovd M, Åsberg A, Munthe LA, Heldal K, Reisæter AV, Vaage JT, et al. Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study. EClinicalMedicine. 2023;60: 102035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242148</ArticleId><ArticleId IdType="pubmed">37362086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Honda A, Kurokawa M. COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2022;22(8):e691–707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8958822</ArticleId><ArticleId IdType="pubmed">35459624</ArticleId></ArticleIdList></Reference><Reference><Citation>Joudeh AI, Lutf AQ, Mahdi S, Tran G. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: a systematic review. Vaccine. 2023;41(26):3801–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201317</ArticleId><ArticleId IdType="pubmed">37244811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JD, Leonard S, Hoggatt KJ, Boscardin WJ, Lum EN, Moss-Vazquez TA, et al. Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA. 2022;328(14):1427–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513709</ArticleId><ArticleId IdType="pubmed">36156706</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022;12(7): e060425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9251904</ArticleId><ArticleId IdType="pubmed">35777878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma BM, Tam AR, Chan KW, Ma MKM, Hung IFN, Yap DYH, et al. Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9: 827859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8959490</ArticleId><ArticleId IdType="pubmed">35355604</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley HJ, Li NC, Aweh GN, Hsu CM, Weiner DE, Miskulin D, et al. SARS-CoV-2 vaccine effectiveness and breakthrough infections among patients receiving maintenance dialysis. Am J Kidney Dis. 2023;81(4):406–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711902</ArticleId><ArticleId IdType="pubmed">36462570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabi Nejad M-M, Moosaie F, Dehghanbanadaki H, Haji Ghadery A, Shabani M, Tabary M, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8840778</ArticleId><ArticleId IdType="pubmed">35151362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabi Nejad M-M, Shobeiri P, Dehghanbanadaki H, Tabary M, Aryannejad A, Haji Ghadery A, et al. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis. Virol J. 2022;19(1):132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358061</ArticleId><ArticleId IdType="pubmed">35941646</ArticleId></ArticleIdList></Reference><Reference><Citation>Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi SA, Bashash D. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. Int Immunopharmacol. 2022;110: 109046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273573</ArticleId><ArticleId IdType="pubmed">35843148</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechotta V, Mellinghoff SC, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022;12(5):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9152308</ArticleId><ArticleId IdType="pubmed">35641489</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2021;35(1): 100588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666542</ArticleId><ArticleId IdType="pubmed">33246166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27(8):1173.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091803</ArticleId><ArticleId IdType="pubmed">33957273</ArticleId></ArticleIdList></Reference><Reference><Citation>Schietzel S, Anderegg M, Limacher A, Born A, Horn MP, Maurer B, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open. 2022;8(1): e002036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814433</ArticleId><ArticleId IdType="pubmed">35115385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis. 2022;74(9):1515–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436392</ArticleId><ArticleId IdType="pubmed">34358310</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar A, Pradhan K, Duva B, Carreno JM, Sahu S, Thiruthuvanathan V, et al. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial. Elife. 2023. 10.7554/eLife.83694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10129324</ArticleId><ArticleId IdType="pubmed">36975207</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabbani D, Yotis DM, Ferreira VH, Shalhoub S, Belga S, Tyagi V, et al. Immunogenicity, safety, and breakthrough severe acute respiratory syndrome coronavirus 2 infections after coronavirus disease 2019 vaccination in organ transplant recipients: a prospective multicenter Canadian Study. Open Forum Infect Dis. 2023. 10.1093/ofid/ofad200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10199121</ArticleId><ArticleId IdType="pubmed">37213422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cdc. COVID-19 Vaccination. Centers for Disease Control and Prevention. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM. Safety monitoring of COVID-19 mRNA vaccine first booster doses among persons aged ≥12 years with presumed immunocompromise status — United States, January 12, 2022–March 28, 2022. MMWR Morb Mortal Wkly Rep. 2022; 10.15585/mmwr.mm7128a3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9290389</ArticleId><ArticleId IdType="pubmed">35834416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6(24):6198–207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561400</ArticleId><ArticleId IdType="pubmed">36538342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. Vaccine. 2023;41(24):3636–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154542</ArticleId><ArticleId IdType="pubmed">37173268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, et al. Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis. Vaccines. 2022;10(5):798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142990</ArticleId><ArticleId IdType="pubmed">35632554</ArticleId></ArticleIdList></Reference><Reference><Citation>Angkasekwinai N, Juthamas P, Leelahavarong P, Sarayuth K, Chatkamol P, Natthakan C, et al. Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis. 2022;40(4):321–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">36681658</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Data &amp; Surveillance | CDC. 2024.</Citation></Reference><Reference><Citation>Azeem MI NA, Shanmugasundaram U, Cheedarla N, Potdar S, Manalo RJ, Moreno A, Switchenko JM, Cheedarla S, Doxie DB, Radzievski R, Ellis ML, Manning KE, Wali B, Valanparambil RM, Maples KT, Baymon E, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Roback JD, Sette A, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV, Dhodapkar KM. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections | Blood Cancer Discovery | American Association for Cancer Research. Blood Cancer Discov. 2023;4(2):106–117).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975771</ArticleId><ArticleId IdType="pubmed">36511813</ArticleId></ArticleIdList></Reference><Reference><Citation>(OIAC) OIAC. Ontario Immunization Advisory Committee (OIAC). Public Health Ontario.</Citation></Reference><Reference><Citation>COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study - PMC.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381025</ArticleId><ArticleId IdType="pubmed">35991760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-C, Lai T-S, Lin S-L, Chen Y-M, Chu T-S, Tu Y-K. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985947</ArticleId><ArticleId IdType="pubmed">33796245</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Malik P, Patel N, Pothuru S, Israni A, Chakinala RC, et al. Kidney disease and COVID-19 disease severity—systematic review and meta-analysis. Clin Exp Med. 2022;22(1):125–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063780</ArticleId><ArticleId IdType="pubmed">33891214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N, Shah S, Paudel K, Chamlagain R, Chhetri S. Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: a systematic review. Health Sci Rep. 2022;5(4): e700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9203992</ArticleId><ArticleId IdType="pubmed">35755410</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiyao R, Mengjie Y, Xiaogang S, Wenfang H, Danna Z, Yuqun Z, et al. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: a systematic review and meta-analysis. Front Public Health. 2022;10: 951096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539993</ArticleId><ArticleId IdType="pubmed">36211647</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. COVID-19 Vaccine: For Public Health Jurisdictions and Dialysis Partners | CDC. 2023.</Citation></Reference><Reference><Citation>Affeldt P, Koehler FC, Brensing KA, Gies M, Platen E, Adam V, et al. Immune response to third and fourth COVID-19 vaccination in hemodialysis patients and kidney transplant recipients. Viruses. 2022;14(12):2646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785871</ArticleId><ArticleId IdType="pubmed">36560648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ontario Immunization Advisory Committee (OIAC) | Public Health Ontario.</Citation></Reference><Reference><Citation>Notarte KI, Catahay JA, Peligro PJ, Velasco JV, Ver AT, Guerrero JJ, et al. Humoral response in hemodialysis patients post-SARS-CoV-2 mRNA vaccination: a systematic review of literature. Vaccines. 2023;11(4):724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10142871</ArticleId><ArticleId IdType="pubmed">37112636</ArticleId></ArticleIdList></Reference><Reference><Citation>S O, K T, M A, Ar O, Mr A, Z A, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dialysis Transplant Eur Renal Assoc 2020;35(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716804</ArticleId><ArticleId IdType="pubmed">33275763</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilhack G, Monteforte R, Frommlet F, Reindl-Schwaighofer R, Strassl R, Vychytil A. Durable anti-SARS-CoV-2 antibody response after mRNA-1273 booster in peritoneal dialysis patients during the omicron wave. Vaccines. 2023;11(6):1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10302227</ArticleId><ArticleId IdType="pubmed">37376510</ArticleId></ArticleIdList></Reference><Reference><Citation>Berar-Yanay N, Freiman S, Shapira MA, Saffoury A, Elemy A, Hamze M, et al. Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. J Clin Med. 2022;11(1):64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745040</ArticleId><ArticleId IdType="pubmed">35011801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults — VISION Network, Nine States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812442</ArticleId><ArticleId IdType="pubmed">36580430</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol. 2023;55(4):791–802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890430</ArticleId><ArticleId IdType="pubmed">36723829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J-J, Lee TH, Tian Y-C, Lee C-C, Fan P-C, Chang C-H. Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10): e2131749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554642</ArticleId><ArticleId IdType="pubmed">34709385</ArticleId></ArticleIdList></Reference><Reference><Citation>Montez-Rath ME, Garcia P, Han J, Cadden L, Hunsader P, Morgan C, et al. SARS-CoV-2 Infection during the omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses. J Am Soc Nephrol. 2022;33(10):1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9528334</ArticleId><ArticleId IdType="pubmed">35973733</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EPK, Horne EMF, Hulme WJ, Tazare J, Zheng B, Carr EJ, et al. Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study. The Lancet Regional Health – Europe. 2023;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10155829</ArticleId><ArticleId IdType="pubmed">37363796</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. 2022;4(11):e775–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381025</ArticleId><ArticleId IdType="pubmed">35991760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood A, Tran M, Murthy V, Gonzalez E. Immunogenicity and safety of SARS-CoV-2 vaccination in patients with rheumatic diseases: a systematic review and meta-analysis. JCR J Clin Rheumatol. 2022;28(8):381.</Citation><ArticleIdList><ArticleId IdType="pubmed">35660717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, et al. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatol. 2023;5(1):e36–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671616</ArticleId><ArticleId IdType="pubmed">36415604</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Recommended update (2023–2024 Formula) COVID19-vaccination-recommendations.</Citation></Reference><Reference><Citation>Mojadadi M-S, Javadinia SA, Attarian F, Samami E, Sobhani M. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: a systematic review with meta-analysis of heterologous versus homologous vaccination. Front Public Health. 2023;10: 960598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878157</ArticleId><ArticleId IdType="pubmed">36711369</ArticleId></ArticleIdList></Reference><Reference><Citation>Control. CoD. COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC. 2024.</Citation></Reference><Reference><Citation>Mehrabi Nejad MM, Shobeiri P, Dehghanbanadaki H, Tabary M, Aryannejad A, Haji Ghadery A, et al. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis. Virol J. 2022;19(1):132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358061</ArticleId><ArticleId IdType="pubmed">35941646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>